Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial)

Wilson Nadruz Jr; Brian L Claggett; John J McMurray; Milton Packer; Michael R Zile; Jean L Rouleau; Akshay S Desai; Karl Swedberg; Martin Lefkowitz; Victor C Shi; Margaret F Prescott; Scott D Solomon

doi:10.1161/CIRCULATIONAHA.116.024976

Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial)

Circulation. 2016 Nov 29;134(22):1785-1787. doi: 10.1161/CIRCULATIONAHA.116.024976.

Affiliations

¹ From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.).
² From Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (W.N., B.L.C., A.S.D., S.D.S.); Department of Internal Medicine, University of Campinas, Campinas, Brazil (W.N.); British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Division of Cardiology, Medical University of South Carolina, Ralph H. Johnston Veterans Administration Medical Center, Charleston (M.R.Z.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); and Novartis Pharmaceuticals Corporation, East Hanover, NJ (M.L., V.C.S., M.F.P.). ssolomon@rics.bwh.harvard.edu.

PMID: 27895026
DOI: 10.1161/CIRCULATIONAHA.116.024976

No abstract available

Keywords: BNP; NT-proBNP; heart failure; natriuretic peptides; obesity; prognosis.

Publication types

Comparative Study
Letter
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Angiotensin II Type 1 Receptor Blockers / adverse effects
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Biomarkers / blood
Body Mass Index*
Chronic Disease
Drug Therapy, Combination
Female
Heart Failure / blood
Heart Failure / drug therapy*
Heart Failure / mortality
Heart Failure / physiopathology
Humans
Male
Middle Aged
Natriuretic Peptide, Brain / blood*
Neprilysin / antagonists & inhibitors
Neprilysin / metabolism
Obesity / diagnosis
Obesity / mortality
Obesity / physiopathology*
Peptide Fragments / blood*
Predictive Value of Tests
Prospective Studies
Protease Inhibitors / adverse effects
Protease Inhibitors / therapeutic use*
Risk Assessment
Risk Factors
Stroke Volume / drug effects*
Time Factors
Treatment Outcome
Ventricular Function, Left / drug effects*

Substances

Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Biomarkers
Peptide Fragments
Protease Inhibitors
pro-brain natriuretic peptide (1-76)
Natriuretic Peptide, Brain
Neprilysin

Associated data

ClinicalTrials.gov/NCT01035255